BioWorld

Aug. 27, 2008

Indevus Closes $105M Note Deal Backed by Sanctura Royalties

Indevus Pharmaceuticals Inc. joined the ranks of biotechs leveraging royalty streams to access nondilutive financing. (BioWorld Today) Read More

QLT Anticipates Excess of Cash Following Atrigel, Other Deals

Restarted Pharmalink Generates Promising Phase III Data in PPS

Novosom In-Licenses Antisense CD40 Inhibitors from Isis Pharma

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 31, 2026.

AIDS 2026: New targets for metabolic dysfunction despite ART

BioWorld

Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...

Jingxin discloses new muscarinic and sigma receptor agonists

BioWorld Science

Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...

Silhouette illustration of DNA gene editing

Death in Chinese gene-editing trial exposes ethical fault lines

BioWorld

The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...

Fauci’s silence may put him in contempt of Congress

BioWorld

After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...